The Systemic Bottleneck: Why Biopharma's Drug Development Crisis Is Organizational, Not Scientific
Key Insights
Analysis of FDA Complete Response Letters from 2020 to 2024 reveals that 74% cited manufacturing or quality issues, pointing to organizational deficiencies rather than scientific failure as the primary constraint in drug development.
Three advanced therapy programs received CRLs on a single day in July 2025 — all for CMC deficiencies — underscoring a structural mismatch between how companies make capital commitment decisions and what compressed timelines now demand.
With 57% of 2024 FDA novel drug approvals involving expedited designations and AI compressing discovery timelines, companies must restructure manufacturing scale-up decisions, embed commercial functions earlier, and develop integrated leadership capable of decision-making under uncertainty.
On a single day in July 2025, three advanced therapy programs each received a Complete Response Letter from the FDA. Capricor (search)'s CAP-1002 for Duchenne muscular dystrophy (search), Ultragenyx's UX111 for Sanfilippo syndrome type A (search), and Rocket Pharmaceuticals' Kresladi for leukocyte adhesion deficiency (search) were all rejected — not for efficacy concerns, but for CMC deficiencies. The rejections were not an anomaly. Analysis of FDA CRLs from 2020 to 2024 showed that 74% cited manufacturing or quality issues, a pattern that predates the current period of FDA leadership change and spans multiple administrations.
The primary constraint in drug development, a growing body of evidence suggests, is no longer scientific or regulatory but organizational. And most biopharma companies are not built for what is coming.
The Acceleration Imperative
In 2024, 57% of FDA novel drug approvals involved at least one expedited designation — whether Breakthrough Therapy, Fast Track, Priority Review, or Accelerated Approval. Rolling review has moved from a pandemic workaround to a standard tool. The FDA has also signaled openness to approving a single well-controlled pivotal trial in certain settings, with confirmatory evidence generated in parallel rather than in sequence.
Simultaneously, artificial intelligence is compressing discovery and development timelines. Tech-first biotech Insilico Medicine (search) moved its idiopathic pulmonary fibrosis (search) candidate from target identification to preclinical nomination in 18 months, against an industry benchmark of two and a half to four years. As Rohit Gupta, Partner at Beghou, notes: "When one part of a system accelerates, the constraint moves. Drug development is moving from evidence generation toward the enterprise that must act on it."
Opting out of accelerated pathways carries its own risks. When a rival earns Breakthrough designation and reaches the market a year ahead in oncology or rare disease, prescribing patterns form, formularies favor the pioneer, and payers establish reference points. The second entrant arrives with opinions already formed.
The Structural Mismatch
The CMC-heavy CRL pattern reflects a structural mismatch between how biopharma organizations make capital commitment decisions and what compressed timelines now demand. Scale-up decisions have historically been made after Phase 3 readout, when probability of approval justified the capital. That logic, while rational when development was long, is now dangerous. Companies must make large, partially irreversible capital commitments under uncertainty that used to be fully resolved before anyone reached for a checkbook.
The market access dimension compounds this pressure. A drug approved by the FDA in early 2026 will typically not reach reimbursed patients in France or England until late 2027 or beyond. Germany's AMNOG process takes a year after launch to reach a negotiated price; the UK's National Institute for Health and Care Excellence runs for nine to 12 months. These timelines do not compress in response to clinical acceleration. Commercial and market access functions must now be active during development, not after. Sequential handoffs that made sense when time was abundant are now self-imposed delays.
Who Is Most Exposed
Large pharma has the infrastructure but often lacks the decision-making apparatus to deploy it in coordination before certainty arrives. With quarterly portfolio reviews, function-level profit and loss, and leadership forums calibrated to a slower evidence environment, the pieces exist but not the operating model for moving them together quickly. Small biotechs can make rapid decisions but often lack the cross-functional depth needed to run parallel workstreams.
The most exposed companies sit in the middle — too large to be genuinely agile yet too small to field teams with the requisite degree of parallel execution. In terms of therapeutic area, oncology teams have operated under compressed timelines for a decade and have built the muscle. Others — cardiovascular, CNS, metabolic disease, and immunology — are less prepared and are rapidly approaching the same predicament.
Three Shifts Required
Fixing this is not a culture initiative, and it cannot be solved by adding a cross-functional task force to an existing sequential operating model. Three structural shifts are required.
First, capital commitment decisions, particularly manufacturing scale-up, must be explicitly restructured to occur earlier and under more uncertainty than current stage-gate frameworks were designed to handle. This means building probabilistic investment models that account for CMC risk alongside clinical risk, with clear ownership at the leadership level for making the call before Phase 3 resolves.
Second, commercial and medical functions must be formally embedded in development-stage planning — not as observers but as contributors to trial design, endpoint selection, and evidence strategy. The pivotal trial is increasingly the commercial blueprint. Organizations that treat it as purely a clinical exercise are making a structural error.
Third, the leadership profile required to run this model needs to be named and developed. The integrated leader who can hold ambiguity across development, regulatory, manufacturing, and commercial functions simultaneously, and make resource allocation calls before the evidence is complete, is a different archetype than the functional depth specialists most biopharma organizations have historically built for. That profile is scarce. Organizations that have not identified it are already behind.
As Gupta concludes: "The biopharma industry spent 30 years arguing that slow development was a problem imposed predominantly from the outside. As some of those external constraints now loosen, a new risk is emerging. Organizations are discovering that the constraint was never entirely outside the building."